These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 20693850)

  • 1. Artificial antigen-presenting cells for use in adoptive immunotherapy.
    Turtle CJ; Riddell SR
    Cancer J; 2010; 16(4):374-81. PubMed ID: 20693850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial Antigen Presenting Cells: An Off the Shelf Approach for Generation of Desirable T-Cell Populations for Broad Application of Adoptive Immunotherapy.
    Hasan AN; Selvakumar A; O'Reilly RJ
    Adv Genet Eng; 2015; 4(3):. PubMed ID: 29644163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial Antigen-Presenting Cells for Immunotherapies.
    Siefert AL; Fahmy TM; Kim D
    Methods Mol Biol; 2017; 1530():343-353. PubMed ID: 28150213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.
    Eggermont LJ; Paulis LE; Tel J; Figdor CG
    Trends Biotechnol; 2014 Sep; 32(9):456-65. PubMed ID: 24998519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
    Butler MO; Hirano N
    Immunol Rev; 2014 Jan; 257(1):191-209. PubMed ID: 24329798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Connecting the dots: artificial antigen presenting cell-mediated modulation of natural killer T cells.
    Sun W; Subrahmanyam PB; East JE; Webb TJ
    J Interferon Cytokine Res; 2012 Nov; 32(11):505-16. PubMed ID: 23050947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
    Rhodes KR; Green JJ
    Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable Cationic Polymer Blends for Fabrication of Enhanced Artificial Antigen Presenting Cells to Treat Melanoma.
    Rhodes KR; Isser A; Hickey JW; Ben-Akiva E; Meyer RA; Kosmides AK; Livingston NK; Tzeng SY; Schneck JP; Green JJ
    ACS Appl Mater Interfaces; 2021 Feb; 13(7):7913-7923. PubMed ID: 33573372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential advantages of CD1-restricted T cell immunotherapy in cancer.
    Consonni M; Dellabona P; Casorati G
    Mol Immunol; 2018 Nov; 103():200-208. PubMed ID: 30308433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-Class II Artificial Antigen Presenting Cells in CD4
    Couture A; Garnier A; Docagne F; Boyer O; Vivien D; Le-Mauff B; Latouche JB; Toutirais O
    Front Immunol; 2019; 10():1081. PubMed ID: 31156634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing human plasmacytoid dendritic cells as professional APCs.
    Tel J; van der Leun AM; Figdor CG; Torensma R; de Vries IJ
    Cancer Immunol Immunother; 2012 Aug; 61(8):1279-88. PubMed ID: 22294456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technological advances in adoptive immunotherapy.
    Oelke M; Krueger C; Schneck JP
    Drugs Today (Barc); 2005 Jan; 41(1):13-21. PubMed ID: 15753966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial antigen-presenting cells are superior to dendritic cells at inducing antigen-specific cytotoxic T lymphocytes.
    Shao J; Xu Q; Su S; Wei J; Meng F; Chen F; Zhao Y; Du J; Zou Z; Qian X; Liu B
    Cell Immunol; 2018 Dec; 334():78-86. PubMed ID: 30392890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surface-Engineering of Red Blood Cells as Artificial Antigen Presenting Cells Promising for Cancer Immunotherapy.
    Sun X; Han X; Xu L; Gao M; Xu J; Yang R; Liu Z
    Small; 2017 Oct; 13(40):. PubMed ID: 28861943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
    Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
    Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality and quantity: new strategies to improve immunotherapy of cancer.
    Krueger C; Schneck JP; Oelke M
    Trends Mol Med; 2004 May; 10(5):205-8. PubMed ID: 15121045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy: good habits instilled at youth have long-term benefits.
    Paulos CM; Suhoski MM; Plesa G; Jiang T; Basu S; Golovina TN; Jiang S; Aqui NA; Powell DJ; Levine BL; Carroll RG; Riley JL; June CH
    Immunol Res; 2008; 42(1-3):182-96. PubMed ID: 18949448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular immunotherapy of cancer.
    Yang JC
    Curr Opin Gen Surg; 1994; ():238-44. PubMed ID: 7583979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro.
    Han H; Peng JR; Chen PC; Gong L; Qiao SS; Wang WZ; Cui ZQ; Yu X; Wei YH; Leng XS
    Biochem Biophys Res Commun; 2011 Aug; 411(3):530-5. PubMed ID: 21756876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.